8ATB

Discovery of IRAK4 Inhibitor 16


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.212 

wwPDB Validation   3D Report Full Report


Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history


Literature

Discovery of IRAK4 Inhibitors BAY1834845 (Zabedosertib) and BAY1830839 .

Bothe, U.Gunther, J.Nubbemeyer, R.Siebeneicher, H.Ring, S.Bomer, U.Peters, M.Rausch, A.Denner, K.Himmel, H.Sutter, A.Terebesi, I.Lange, M.Wengner, A.M.Guimond, N.Thaler, T.Platzek, J.Eberspacher, U.Schafer, M.Steuber, H.Zollner, T.M.Steinmeyer, A.Schmidt, N.

(2024) J Med Chem 67: 1225-1242

  • DOI: https://doi.org/10.1021/acs.jmedchem.3c01714
  • Primary Citation of Related Structures:  
    8ATB, 8ATL, 8ATN, 8BR5, 8BR6, 8BR7

  • PubMed Abstract: 

    Interleukin-1 receptor-associated kinase 4 (IRAK4) plays a critical role in innate inflammatory processes. Here, we describe the discovery of two clinical candidate IRAK4 inhibitors, BAY1834845 (zabedosertib) and BAY1830839 , starting from a high-throughput screening hit derived from Bayer's compound library. By exploiting binding site features distinct to IRAK4 using an in-house docking model, liabilities of the original hit could surprisingly be overcome to confer both candidates with a unique combination of good potency and selectivity. Favorable DMPK profiles and activity in animal inflammation models led to the selection of these two compounds for clinical development in patients.


  • Organizational Affiliation

    Bayer AG, Research & Development, Pharmaceuticals, 13353 Berlin, Germany.


Macromolecules
Find similar proteins by:  (by identity cutoff)  |  3D Structure
Entity ID: 1
MoleculeChains Sequence LengthOrganismDetailsImage
Interleukin-1 receptor-associated kinase 4A [auth AAA],
B [auth BBB]
298Homo sapiensMutation(s): 3 
Gene Names: IRAK4
EC: 2.7.11.1
UniProt & NIH Common Fund Data Resources
Find proteins for Q9NWZ3 (Homo sapiens)
Explore Q9NWZ3 
Go to UniProtKB:  Q9NWZ3
PHAROS:  Q9NWZ3
GTEx:  ENSG00000198001 
Entity Groups  
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9NWZ3
Sequence Annotations
Expand
  • Reference Sequence
Small Molecules
Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
O0H (Subject of Investigation/LOI)
Query on O0H

Download Ideal Coordinates CCD File 
C [auth AAA],
E [auth BBB]
~{N}-[6-ethoxy-2-[2-(4-methylpiperazin-1-yl)-2-oxidanylidene-ethyl]indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
C23 H25 F3 N6 O3
AIMNCVIDWQOVPW-UHFFFAOYSA-N
GOL
Query on GOL

Download Ideal Coordinates CCD File 
D [auth AAA]GLYCEROL
C3 H8 O3
PEDCQBHIVMGVHV-UHFFFAOYSA-N
Modified Residues  3 Unique
IDChains TypeFormula2D DiagramParent
CSO
Query on CSO
A [auth AAA],
B [auth BBB]
L-PEPTIDE LINKINGC3 H7 N O3 SCYS
SEP
Query on SEP
A [auth AAA],
B [auth BBB]
L-PEPTIDE LINKINGC3 H8 N O6 PSER
TPO
Query on TPO
A [auth AAA],
B [auth BBB]
L-PEPTIDE LINKINGC4 H10 N O6 PTHR
Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.35 Å
  • R-Value Free: 0.260 
  • R-Value Work: 0.212 
  • Space Group: I 2 2 2
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 87.2α = 90
b = 117.5β = 90
c = 136.6γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
XDSdata reduction
XSCALEdata scaling
MOLREPphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History & Funding Information

Revision History  (Full details and data files)

  • Version 1.0: 2023-11-29
    Type: Initial release
  • Version 1.1: 2024-01-31
    Changes: Database references
  • Version 1.2: 2024-02-07
    Changes: Database references